Novavax to seek full approval for COVID-19 vaccine in second half of 2022
Novavax plans to pursue full approval for its COVID-19 vaccine during the second half of 2022, following a late-stage study showing sustained efficacy and a forecast of $4 billion to $5 billion in revenue.
Herald Premium Archive
This report is for subscribers
Sign in or choose a plan for full access to every Belfast Herald story and the complete archive.
HealthNovavax to seek full approval for COVID-19 vaccine in second half of 2022
Sign in or subscribeBrowse free archive reportsNovavax plans to pursue full approval for its COVID-19 vaccine during the second half of 2022, following a late-stage study showing sustained efficacy and a forecast of $4 billion to $5 billion in revenue.